Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing

BIQIANG ZHENG^{1,2}, SHUIRONG ZHANG³, WEILUO CAI^{1,2}, JIAN WANG^{1,4},
TING WANG⁵, NING TANG⁵, YINGQIANG SHI^{1,2}, XIAOYING LUO⁵ and WANGJUN YAN^{1,2}

¹Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China;

²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China;

³Origimed, Shanghai, P.R. China;

⁴Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China;

⁵State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China

Abstract. *Background/Aim:* Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal neoplasm characterized by chromosomal instability. The aim of this study was to identify fusion events involved in UPS. *Materials and Methods:* Transcriptome sequencing was performed to search for new fusion genes in 19 UPS samples, including two paired recurrent (R) and re-recurrent (RR) samples. *Results:* A total of 66 fusion genes were detected. Among them, 10 novel fusion genes were further confirmed by reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing. Retinoblastoma (RB1) fusions (2 cases) were the most recurrent fusion genes. The gene fusions RB1-RNASEH2B, RB1-FGF14-AS1, and E2F6-FKBP4 were correlated with the Rb/E2F pathway. Pseudogenes were involved in the formation of the gene fusions CIC-DUX4L8 and EIF2AK4-ANXA2P2. Importantly, targetable gene fusions (PDGFRA-MACROD2 and NCOR1-MAP2K1) were detected in UPS. *Conclusion:* Screening for the presence of fusion transcripts will provide vital clues to the understanding of genetic alterations and the finding of new targeted therapies for UPS.

This article is freely accessible online.

Correspondence to: Dr. Wangjun Yan, Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, No. 270, Dongan Road, Shanghai 200032, P.R. China. Tel/Fax: +86 2164430130, e-mail: spinetumor@163.com; Dr. Xiaoying Luo, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, No. 25, Xietu Road 2200, Shanghai 200032, P.R. China. Tel/Fax: +86 2164436795, e-mail: luoxiy@shsci.org

Key Words: Soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, fusion gene, RB1, pseudogene, targetable fusion.

Undifferentiated pleomorphic sarcoma (UPS) is one of the most common soft tissue sarcomas, and represents an aggressive type of mesenchymal malignancy with no identifiable line of differentiation (1). Surgery, radiotherapy, and chemotherapy are the main treatments for UPS. However, UPS tends to recur and spreads to other organs (mainly the lungs), and the 5-year survival rate remains low (30-50%) (1). Therefore, investigations into the underlying mechanisms involved in UPS initiation and progression are of major importance and may lead to the development of new approaches for these patients with poor prognosis.

We and others have found that *TP53*, *ATRX*, and *RB1* are highly mutated in UPS (2, 3); however, no specific genetic characteristics have been identified for UPS compared with other soft tissue sarcomas [such as *c-kit* mutation for gastrointestinal stromal tumor (4), *SS18-SSX1* fusion for synovial sarcoma and so on (5)]. Gene fusions are common in leukemia, bone and soft tissue tumors (6). Almost 300 gene fusions have been detected in mesenchymal tumors (5). Many gene fusions are driver mutations and provide new insights into the molecular mechanisms that are involved in tumorigenesis. These may serve diagnostic or risk stratification purposes and specific targets (5, 7). Some gene fusions (*PRDM10* and *TRIO* fusions) have been reported in a small number of UPS cases (8, 9). However, UPS is heterogeneous at the genomic level, displaying a spectrum of genomic instability mostly driven by massive copy number changes and large structural rearrangements (10, 11). Many gene fusions may represent chance events that result from chromosomal instability (12). Therefore, we hypothesized that more fusion genes may exist in UPS.

In an attempt to identify new fusion genes in UPS, we performed transcriptome sequencing on 19 UPS samples, including two paired recurrent (R) and re-recurrent (RR) samples. In this study, 66 fusion genes were found. Among

them, 10 novel fusion transcripts were further verified by reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing.

Materials and Methods

Patients. Seventeen patients diagnosed with UPS (the criteria: 1. No identifiable line of differentiation; 2. Tumor cells showing a high degree of pleomorphism) by two professional bone and soft tissue pathologists were included in this study. Four μ m hematoxylin and eosin stained slides of each tumor were reviewed, a minimum tumor content of 20% was observed for all cases. Of the 17 patients, one case had a primary tumor resection three years earlier and developed lung metastasis, three cases were newly diagnosed, and 13 patients were relapsed at admission. Tumor tissues and matched adjacent normal muscle tissues were frozen and stored at -80°C. Tumor, node, and metastasis (TNM) staging was determined using the 7th edition of the American Joint Committee on Cancer guideline of TNM classification. All patients provided written informed consent, and the study was approved by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center (Number: 050432-4-1805C).

RNA extraction. Total RNA was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from fresh frozen UPS samples and matched adjacent normal muscle tissue samples according to the manufacturer's instructions. The quantity and quality of RNA were evaluated by the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples with a RIN score >7 and RNA concentration >1000 ng were selected for library preparation.

RNA sequencing. One microgram of total RNA from UPS samples was used for library preparation, which was conducted by using the TruSeq RNA Library Prep Kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. The final libraries were sequenced on an Illumina HiSeqXten platform with a paired-end 2x150 bp protocol aiming at 8 Gb per sample. To discover the fusion transcripts, the RNA-Seq data was analyzed by the STAR-Fusion software (13, 14). In Star-Fusion, a built-in GRCh38 reference genome was used with Gencode v26 annotation. Fusion transcripts were found by Star-Fusion with default parameters, and at least three spanning read pairs and three split-reads were required for each fusion (14). In this study, the matched adjacent normal muscle tissue samples were not subjected to RNA sequencing.

RT-PCR and Sanger sequencing. The primers used for PCR amplification and sequencing are listed in Table I. For RT-PCR, 1 μ g of total RNA was reverse-transcribed in a 20- μ l reaction volume using a FastKing RT Kit (with gDNase) according to the manufacturer's instructions (Tiangen Biotech, Beijing, China). PCR amplification was performed using PrimeSTAR Max DNA Polymerase (Takara). PCR products were analyzed by agarose gel electrophoresis. All positive RT-PCR products were confirmed by Sanger sequencing. The BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) was used for the analysis of sequence data.

Immunohistochemical analysis. Immunohistochemical analysis was performed on 4- μ m-thick tumor sections according to standard procedures. The tissue sections were dewaxed and retrieved, and endogenous peroxidase activity was blocked by hydrogen peroxide

Table I. Primers used for RT-PCR of gene fusions.

Primer	Sequence (5'-3')
C15orf57-CBX3	
C15orf57-CBX3 F	CCTACTGTTGGTTGCCCGT
C15orf57-CBX3 R	CTCTTTCGCCAGCACCAAGT
CIC-DUX4L8	
CIC-DUX4L8 F	CTCTGTGGACAACAGGGTCC
CIC-DUX4L8 R	GAGCCTGAGGGTGGGAGA
E2F6-FKBP4	
E2F6-FKBP4 F	CCTCTTTTTCGCTGCGTC
E2F6-FKBP4 R	CACCTCATTTGGGCTTAGCA
EIF2AK4-ANXA2P2	
EIF2AK4-ANXA2P2 F	CAACAGCTTTCTGCCCCTG
EIF2AK4-ANXA2P2 R	GGTGACCTCATCCACACCTTT
MAPK10-SPARCL1	
MAPK10-SPARCL1 F	ATAGCAACCCCATTCGCCAA
MAPK10-SPARCL1 R	TGTTGTGAGGTGCTACCGTT
NCOR1-MAP2K1	
NCOR1-MAP2K1 F	AGAGGGGTTGAGTCAAGATGG
NCOR1-MAP2K1 R	TGGAGGAGGCTCGTTGACTA
RB1-FGF14-AS1	
RB1-FGF14-AS1 F	TTTATTGGCGTGCGCTCTTG
RB1-FGF14-AS1 R	TGAAGTAGCATTGCAGCACTTT
RB1-RNASEH2B	
RB1-RNASEH2B F	TCTTTATTGGCGTGCGCTCT
RB1-RNASEH2B R	CACAGGTGTGGCAAAATGGAG
RICTOR-CCDC152	
RICTOR-CCDC152 F	GGTGTGTGACTGAAACCCG
RICTOR-CCDC152 R	CTTTGCCAACAGAAAGGCGT
RORA-AC011526.1	
RORA-AC011526.1 F	GATAGAGGGAGTCTCGGAGC
RORA-AC011526.1 R	TCCCAGACCCAAGGCTTACA
RORA-LHFP	
RORA-LHFP F	GCCATCTCCAGCGATCTCTAC
RORA-LHFP R	TTCTTGCCCGAAAAGCAAGC
PDGFRA-MACROD2	
PDGFRA-MACROD2 F	AAAAGCGAAGGCGCAATCTG
PDGFRA-MACROD2 R	TGATCTGTCACTTCACCGCC

F: Forward; R: reverse.

treatment. Following incubation with protein blocking solution, slides were incubated at 4°C overnight with an RB1 antibody (1:600, 9309, against the C-Terminus of RB1, Cell Signaling Technology), PDGFRA antibody (1:400, ab203491), and MAP2K1 antibody (1:100, ab32576, against the C-Terminus of MAP2K1). Signal amplification was performed using the IHC Detection Kit (KIT-5920, Fuzhou Maixin Biotechnology, Fujian, China).

Results

Detection of fusion genes in UPS. To identify fusion transcripts, we performed RNA-sequencing in 19 UPS samples, including two paired recurrent (R) and re-recurrent (RR) samples. The clinicopathological characteristics of patients are listed in Table II. STAR-Fusion software was used for analyzing the sequencing data, and 66 fusion genes

Table II. Characteristics of patients.

Patient ID	Gender	Age	Localization	Status at admission	TNM stage	Survival
1	Male	63	Upper extremity	Recurrence	III	Dead
2	Male	57	Lower extremity	Recurrence	III	Dead
3	Male	62	Lower extremity	Recurrence	III	Alive
4	Male	53	Upper extremity	Recurrence	III	Alive
5	Male	62	Lower extremity	Recurrence	II	Alive
6	Female	53	Lung	Metastasis	IV	Dead
7	Female	69	Trunk	Primary	III	Dead
8	Male	57	Trunk	Recurrence	III	Alive
9	Male	62	Lower extremity	Primary	III	Dead
10	Female	55	Lower extremity	Recurrence	III	Dead
11	Male	49	pelvic cavity	Recurrence	III	Dead
12	Male	48	Lower extremity	Recurrence	III	Dead
13	Male	48	Lower extremity	Primary	III	Dead
14	Female	17	Trunk	Recurrence	III	Dead
15	Male	71	Trunk	Recurrence	II	Alive
16R	Female	42	Lower extremity	Recurrence	II	Alive
16RR	Female	43	Lower extremity	Recurrence	II	Alive
17R	Male	66	Trunk	Recurrence	III	Dead
17RR	Male	67	Trunk	Recurrence	III	Dead

R: Recurrence; RR: re-recurrence.

were found. The gene fusions are shown in Figure 1A. The number of fusion genes varied in different patients (Figure 1B). Of the 17 patients, one patient (ID 13) harbored the largest number of gene fusions (n=17), and 4 patients (ID7, 8, 10, 17R) showed no fusion genes. Interestingly, the RR tumor (ID 17RR) showed a new fusion gene, *ZSWIM6-LDB2*. Another RR sample (ID 16RR) displayed the same number of fusion genes compared with the paired R sample (ID 16R). However, two fusion genes (*C15orf57-CBX3* and *RNF24-MACROD2*) were newly detected, whereas two fusions (*COIL-SHISA6* and *PPAP2A-DNAJA3*) were lost in the RR UPS (ID 16RR) compared with paired R UPS (ID 16R); three fusion genes (*DLEU2-FAM124A*, *RB1-FGF14-AS1* and *RORA-LHFP*) showed no change after tumor re-recurrence. No relationship was found between gene fusions and survival in this study.

A few gene fusions (PRDM10 and TRIO fusions) have been reported in a small number of UPS cases (8, 9). However, in this study, we found many fusion genes (n=66). Most of the gene fusions that were recurrent in different cases or whose gene partner affects proliferation were selected and confirmed by RT-PCR and Sanger sequencing; these may be neoplasia-associated gene fusions. *C15orf57-CBX3*, *RORA* fusions and *RB1* fusions were selected as the most recurrent fusions and were observed in 2 patients each. Twelve fusion genes (*C15orf57-CBX3*, *RORA-AC011526.1*, *RORA-LHFP*, *RB1-RNASEH2B*, *RB1-FGF14-AS1*, *E2F6-FKBP4*, *CIC-DUX4L8*, *EIF2AK4-ANXA2P2*, *PDGFRA-MACROD2*, *NCOR1-MAP2K1*, *MAPK10-SPARCL1* and *RICTOR-CCDC152*) were

further analysed in this study. Only one fusion (*RORA-AC011526.1*) could not be detected by RT-PCR (data not shown), although additional paired primers were used. Eleven fusions were confirmed by Sanger sequencing (Figures 2-5). The fusion genes were specifically found in UPS compared with corresponding normal tissues, except for one fusion gene (*C15orf57-CBX3*) that was observed both in the tumor and the corresponding normal tissue (patient ID 14, data not shown), which is consistent with a report indicating that *C15orf57-CBX3* is found in healthy humans (15). To our knowledge, 10 gene fusions (*RB1-RNASEH2B*, *RB1-FGF14-AS1*, *E2F6-FKBP4*, *CIC-DUX4L8*, *EIF2AK4-ANXA2P2*, *PDGFRA-MACROD2*, *NCOR1-MAP2K1*, *MAPK10-SPARCL1*, *RICTOR-CCDC152*, and *RORA-LHFP*) were confirmed for the first time in malignant diseases. Regarding the three recurrent fusions, *RORA-AC011526.1* fusion could not be verified by RT-PCR, *C15orf57-CBX3* fusion was not tumor-associated as it was also detected in normal tissue, and *RB1* fusions (two cases) were identified as the most recurrent fusion genes in this study.

Gene fusions correlated with the Rb/E2F pathway. *RB1* mutation is a common event in UPS (2, 3). However, reports on *RB1* fusion are scant. Interestingly, we found two patients harboring *RB1* fusion genes. One case with *RB1-FGF14-AS1* fusion (Figure 2A and B) had four local recurrences, and the re-recurrent tumor also showed the same fusion (Figure 2A). The patient had to undergo hindquarter amputation to control tumor recurrence, and is still alive, without tumor relapse and metastasis for three years. Another patient with the *RB1-*

Figure 1. Overview of fusion genes detected in UPS. A. Circle plot for fusion transcripts is presented. B. The number of fusion genes in different patients. R: Recurrence; RR: re-recurrence.

RNASEH2B fusion (Figure 2C and D) died of lung metastasis. Rb/E2F pathway dysregulation is a key factor in the pathogenesis of malignant diseases, and E2F-6 acts as a transcriptional repressor (16, 17). We found a new *E2F6-FKBP4* fusion transcript consisting of the first exon of the *E2F6* gene fused to exon 2 of the *FKBP4* gene (Figure 2E and F), which may disrupt the Rb/E2F pathway in UPS. Moreover, expression of the *RBI* protein was scarcely observed or only observed in few cells of the two patients with the *RB1* fusion compared with the patient with no *RB1* fusion (Figure 2G-K).

Pseudogenes are involved in formation of gene fusion. A pseudogene is a non-coding gene that is not producing protein (18). In this study, we identified two fusion genes (*CIC-DUX4L8*, *EIF2AK4-ANXA2P2*) (Figure 3) with pseudogene partners (*DUX4L8*, *ANXA2P2*).

Targetable gene fusions. Some fusions represent a potential therapeutic target (19). Transcriptome sequencing of 19 UPS samples showed that 1 case with metastasis in the lung harboring *PDGFRA-MACROD2* fusion (Figure 4A and B) could be treated with tyrosine kinase inhibitor, which has been shown to be effective in the management of patients with *PDGFRA* fusions (19, 20). The *PDGFR* gene has a breakpoint between exon 1 and exon 2 (Figure 4B); however, the coding sequence for *PDGFR* begins at the second exon. Immunohistochemical staining was performed to detect the impact of *PDGFRA-MACROD2* fusion on the expression of *PDGFRA* protein. High expression of *PDGFRA* was observed in the patient with

PDGFRA-MACROD2 fusion compared with the patient without the *PDGFRA-MACROD2* fusion (Figure 4C-E).

MAP2K1, also known as MEK1, is a key ‘gatekeeper’ of ERK signaling, making MEK inhibition a promising strategy for the treatment of various tumors (21-23). We not only found a novel *NCOR1-MAP2K1* fusion gene as described in Figure 4F and 4G, but also uncovered strong diffuse immunoreactivity by immunohistochemistry using an antibody to the C terminus of MAP2K1.

Other confirmed fusions in UPS. Three other fusions were also confirmed by RT-PCR and Sanger sequencing. One case harbored a fusion between exon 2 of the *MAPK10* and exon 3 of *SPARCL1* gene (Figure 5A and B). Another patient displayed a RICTOR-CCDC152 fusion (Figure 5C and D). A fusion transcript *RORA-LHFP* composed of *RORA* exon 1 fused to *LHFP* exon 3 is shown in Figure 5E and F. The three fusion genes are speculated to be involved in tumor growth, as their partners have important roles in malignant diseases (24-26).

Discussion

UPS is a heterogeneous disease with no definitive cell of origin or specific genetic markers. Fusion genes are considered to have one of the most cancer-specific signatures (27). However, only a few gene fusions have been reported in UPS (8, 9). We identified 10 novel fusion transcripts, including *RBI-RNASEH2B*, *RBI-FGF14-AS1*, *PDGFRA-*

Figure 2. Gene fusions correlated with the Rb/E2F pathway. A. Confirmation of the RB1-FGF14-AS1 fusion by RT-PCR for patient ID16. B. Schematic representation of the sequence around the junction point (vertical line) is shown for the RB1-FGF14-AS1 fusion. C. Confirmation of the RB1-RNASEH2B fusion by RT-PCR for patient ID 6. D. Schematic representation of the sequence around the junction point (vertical line) is shown for RB1-RNASEH2B fusion. E. Confirmation of the E2F6-FKBP4 fusion by RT-PCR for patient ID 1. F. Schematic representation of the sequence around the junction point (vertical line) is shown for the E2F6-FKBP4 fusion. G. H&E staining of UPS for patient ID16. H. Immunohistochemical analysis of RB1 expression in STS for patient ID16. I. H&E staining of UPS for patient ID 6. J. Immunohistochemical analysis of RB1 expression in STS for patient ID 6. K. Positive expression of RB1 in UPS without RB1 fusion. M: DNA marker; C: Paired normal tissue; Original magnification (G-K), $\times 400$.

MACROD2, *MAPK10-SPARCL1*, *CIC-DUX4L8*, *EIF2AK4-ANXA2P2*, *RICTOR-CCDC152*, *E2F6-FKBP4*, *NCOR1-MAP2K1*, and *RORA-LHFP*. RB1 fusions (2/17 cases) were the most recurrent fusion genes in this study. Pseudogenes were involved in the formation of gene fusions. The fusion transcripts were associated with the Rb/E2F pathway and may be targets for treatment. The characterization of UPS-associated gene fusions is beneficial for our general understanding of pathogenetic mechanisms and may also improve patient management.

RB1, the first tumor suppressor gene to be identified, acts as a negative regulator of E2F-regulated transcription (16). RB1 mutations at variable frequencies have been confirmed in various tumors, and RB1 loss can induce indefinite cell division (2, 16). In this study, RB1 fusions (2 cases) were found to be the most recurrent fusion genes. *RB1* was respectively fused to *RNASEH2B* and *FGF14-AS1* (Figure 2A-D). Moreover, expression of RB1 protein was scarcely observed or only observed in few cells (Figure 2G-K), indicating that *RB1* fusions lead to loss of RB1 expression.

Figure 3. Pseudogene is involved in the formation of gene fusion. A. Confirmation of the *CIC*-*DUX4L8* fusion by RT-PCR for patient ID14. B. Schematic representation of the sequence around the junction point (vertical line) is shown for *CIC*-*DUX4L8* fusion. C. Confirmation of the *EIF2AK4*-*ANXA2P2* fusion by RT-PCR for patient ID 13. D. Schematic representation of the sequence around the junction point (vertical line) is shown for the *EIF2AK4*-*ANXA2P2* fusion. M: DNA marker; C: paired normal tissue.

Our data enrich the knowledge on *RB1* genetic aberration caused by gene fusion and suggest that *RB* gene fusion is an important event in UPS. Interestingly, in another case, a *FKBP4* fusion with *E2F6* was detected, which is associated with the Rb/E2F pathway. Taken together, our results suggest that gene fusions (*RB1*-*RNASEH2B*, *RB1*-*FGF14-AS1* and *E2F6*-*FKBP4*) correlated with the Rb/E2F pathway may play important roles in sustaining tumor cell growth in UPS.

Pseudogenes, as non-coding genes, have lost the ability to produce proteins (18). Emerging evidence suggest that pseudogenes play an important role in the pathogenesis of various tumors (18, 28). However, few studies have reported that pseudogenes are involved in the formation of gene fusions. Interestingly, we observed two novel pseudogene fusions (*EIF2AK4*-*ANXA2P2* and *CIC*-*DUX4L8*) (Figure 3). *EIF2AK4*, also known as *GCN2*, a stress-activated protein kinase, has been shown to promote tumor growth and angiogenesis (29), and its function may be affected by the fusion with pseudogene *ANXA2P2*. Another gene, *CIC*, a transcriptional repressor, which has a tumor suppressive function in glioblastoma (30), was found to be fused with the pseudogene *DUX4L8*. These data suggest a new mechanism of genetic disorder involving pseudogenes.

Gene fusions provide important clues to the precise diagnoses and classifications (5). For example, compared with Ewing sarcoma, tumors containing *CIC*-rearrangements are taken as an independent tumor type with distinct clinicopathological features (31, 32). One patient was found

to have a fusion of *CIC* with a new partner (*DUX4L8*) (Figure 3A and B). The patient developed lung metastasis following previous surgery in her right thigh and died of disseminated disease, which is consistent with Antonescu's study (31) indicating that tumors containing *CIC* rearrangements are associated with an aggressive clinical course. Therefore, tumors containing *CIC* rearrangements should be treated with more aggressive approaches.

Gene fusions provide important clues for targeted therapy (26). In UPS, the data on fusion gene-guided therapy are limited. Zhou *et al.* have reported a case with a lumbosacral UPS harboring a *LMNA*-*NTRK1* gene fusion. The patient showed a near-complete clinical response to crizotinib (33). In this study, one case was found to harbor three fusion genes (*PDGFRA*-*MACROD2*, *RB1*-*RNASEH2B*, and *PLXDC2*-*ZEB1*) in lung metastasis. Among these, *PDGFRA*-*MACROD2* can be a direct treatment target, as patients with *PDGFRA* or *PDGFRB* fusions often respond to tyrosine kinase inhibitor therapy (19). Unfortunately, the patient died of tumor metastasis without using targeted therapy. Another patient harboring an *NCOR1*-*MAP2K1* fusion showed aberrant expression of *MAP2K1* (Figure 4I), which can be treated with MEK inhibitors (22, 23), but he showed no local recurrence and metastasis for 4 years after our extensive resection of the tumor in the right upper extremity. In this study, we selected 12 fusion transcripts for verification, and 11 gene fusions were confirmed by RT-PCR and Sanger sequencing, indicating transcriptome sequencing is a reliable approach for detecting

Figure 4. Targetable gene fusions. A. Confirmation of the PDGFRA-MACROD2 fusion by RT-PCR for patient ID 6. B. Schematic representation of the sequence around the junction point (vertical line) is shown for the PDGFRA-MACROD2 fusion. C. H&E staining of UPS for patient ID 6. D. High expression of PDGFRA for patient ID 6. E. Low expression of PDGFRA in a patient without PDGFRA-MACROD2 fusion. F. Confirmation of the NCOR1-MAP2K1 fusion by RT-PCR for patient ID 4. G. Schematic representation of the sequence around the junction point (vertical line) is shown for the NCOR1-MAP2K1 fusion. H. H&E staining of UPS for patient ID 4. I. Abnormally strong expression of MAP2K1 for patient ID 4. J. Low expression of MAP2K1 in a patient without the NCOR1-MAP2K1 fusion. M: DNA marker; C: paired normal tissue; Original magnification (C-E, H-J), $\times 400$.

fusion genes. Moreover, we found 66 fusion genes in 19 UPS samples, and fusion genes were positive in 14 (82%) of 17 patients, suggesting UPS is a translocation-related sarcoma. Trabectedin, a DNA-binding agent with multiple mechanisms of interfering with several transcription factors and DNA-binding proteins, has shown more clinical benefits in

translocation-related sarcoma than those without translocations (34). It has also been reported that trabectedin provides a clinical benefit in UPS patients, and the disease control rate is 56% (5/9) (35). Our results indicate that targeted therapy and trabectedin may show great promise in some selected UPS patients through transcriptome sequencing.

Figure 5. Other confirmed fusions in UPS. A. Confirmation of the MAPK10-SPARCL1 fusion by RT-PCR for patient ID 15. B. Schematic representation of the sequence around the junction point (vertical line) is shown for MAPK10-SPARCL1 fusion. C. Confirmation of the RICTOR-CCDC152 fusion by RT-PCR for patient ID 13. D. Schematic representation of the sequence around the junction point (vertical line) is shown for the RICTOR-CCDC152 fusion. E. Confirmation of the RORA-LHFP fusion by RT-PCR for patient ID 16. F. Schematic representation of the sequence around the junction point (vertical line) is shown for the RORA-LHFP fusion. M: DNA marker; C: paired normal tissue; R: recurrence; RR: re-recurrence.

In this study, gene fusions were frequently observed in UPS. Novel recurrent *RB1* fusion genes were found that were accompanied with loss of *RB1* expression. Pseudogenes were involved in gene fusions. Moreover, some fusion transcripts were associated with the Rb/E2F pathway and targeted treatment. Screening for the presence of fusion transcripts in UPS will provide vital clues to understanding genetic alterations and finding new targeted therapies.

Conflicts of Interest

The Authors disclose no potential conflicts of interest regarding this study.

Authors' Contributions

BZ, XL, and WY designed the study. BZ, SZ, WC, JW, TW, NT, and YS carried out experiments. SZ analyzed the RNA-Seq data. BZ, XL, and WY wrote the manuscript.

Acknowledgements

Funding: This study was supported by grants from the National Natural Science Foundation of China (Grant No: 81472480, 81302103) and Research Project of Shanghai Municipal Health and Family Planning Commission (Grant No:201640261, 20164y0228).

References

- Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ and Robbins AS: Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. *J Am Coll Surg* 210(2): 191-198 e192, 2010. PMID: 20113939. DOI: 10.1016/j.jamcollsurg.2009.10.007
- Cancer Genome Atlas Research Network. Electronic address edsc and Cancer Genome Atlas Research N: Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. *Cell* 171(4): 950-965 e928, 2017. PMID: 29100075. DOI: 10.1016/j.cell.2017.10.014

- 3 Zheng B, Qu Y, Wang J, Shi Y and Yan W: Pathogenic and targetable genetic alterations in resected recurrent undifferentiated pleomorphic sarcomas identified by targeted next-generation sequencing. *Cancer Genomics Proteomics* 16(3): 221-228, 2019. PMID: 31018952. DOI: 10.21873/cgp.20127
- 4 Palmirotta R, De Marchis ML, Ludovici G, Leone B, Covello R, Conti S, Costarelli L, Della-Morte D, Ferroni P, Roselli M and Guadagni F: Mutational analysis of gastrointestinal stromal tumors (gists): Procedural approach for diagnostic purposes. *Cancer Genomics Proteomics* 10(3): 115-123, 2013. PMID: 23741027.
- 5 Nakano K and Takahashi S: Translocation-related sarcomas. *Int J Mol Sci* 19(12), 2018. PMID: 30487384. DOI: 10.3390/ijms19123784
- 6 Mitelman F, Johansson B and Mertens F: The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer* 7(4): 233-245, 2007. PMID: 17361217. DOI: 10.1038/nrc2091
- 7 Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V and Pesta M: Prognostic significance of tmprss2-erg fusion gene in prostate cancer. *Anticancer Res* 36(9): 4787-4793, 2016. PMID: 27630329. DOI: 10.21873/anticancer.11037
- 8 Hofvander J, Tayebwa J, Nilsson J, Magnusson L, Brosjo O, Larsson O, Vult von Steyern F, Mandahl N, Fletcher CD and Mertens F: Recurrent prdm10 gene fusions in undifferentiated pleomorphic sarcoma. *Clin Cancer Res* 21(4): 864-869, 2015. PMID: 25516889. DOI: 10.1158/1078-0432.CCR-14-2399
- 9 Delespaul L, Lesluyes T, Perot G, Brulard C, Lartigue L, Baud J, Lagarde P, Le Guellec S, Neuville A, Terrier P, Vince-Ranchere D, Schmidt S, Debant A, Coindre JM and Chibon F: Recurrent trio fusion in nontranslocation-related sarcomas. *Clin Cancer Res* 23(3): 857-867, 2017. PMID: 27528700. DOI: 10.1158/1078-0432.CCR-16-0290
- 10 Gibault L, Perot G, Chibon F, Bonnin S, Lagarde P, Terrier P, Coindre JM and Aurias A: New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. *J Pathol* 223(1): 64-71, 2011. PMID: 21125665. DOI: 10.1002/path.2787
- 11 Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H, Fittall M, Lombard P, Martincorena I, Tarpey PS, Collord G, Haase K, Strauss SJ, Berisha F, Vaikkinen H, Dhani P, Jansen M, Behjati S, Amary MF, Tirabosco R, Feber A, Campbell PJ, Alexandrov LB, Van Loo P, Flanagan AM and Pillay N: Undifferentiated sarcomas develop through distinct evolutionary pathways. *Cancer Cell* 35(3): 441-456 e448, 2019. PMID: 30889380. DOI: 10.1016/j.ccell.2019.02.002
- 12 Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H and Verhaak RG: The landscape and therapeutic relevance of cancer-associated transcript fusions. *Oncogene* 34(37): 4845-4854, 2015. PMID: 25500544. DOI: 10.1038/nc.2014.406
- 13 Haas B, Dobin A, Stransky N, Li B, Yang X, Tickle T, Bankapur A, Ganote C, Doak T, Pochet N, Sun J, Wu C, Gingeras T and Regev A: STAR-Fusion: Fast and accurate fusion transcript detection from RNA-Seq. 2017. DOI: 10.1101/120295. Available at: <https://www.biorxiv.org/content/early/2017/03/24/120295.full.pdf> (last accessed July 4, 2019)
- 14 Dixon JR, Xu J, Dileep V, Zhan Y, Song F, Le VT, Yardimci GG, Chakraborty A, Bann DV, Wang Y, Clark R, Zhang L, Yang H, Liu T, Iyyanki S, An L, Pool C, Sasaki T, Rivera-Mulia JC, Ozadam H, Lajoie BR, Kaul R, Buckley M, Lee K, Diegel M, Pezic D, Ernst C, Hadjur S, Odom DT, Stamatoyannopoulos JA, Broach JR, Hardison RC, Ay F, Noble WS, Dekker J, Gilbert DM and Yue F: Integrative detection and analysis of structural variation in cancer genomes. *Nat Genet* 50(10): 1388-1398, 2018. PMID: 30202056. DOI: 10.1038/s41588-018-0195-8
- 15 Schrider DR, Navarro FC, Galante PA, Parmigiani RB, Camargo AA, Hahn MW and de Souza SJ: Gene copy-number polymorphism caused by retrotransposition in humans. *PLoS Genet* 9(1): e1003242, 2013. PMID: 23359205. DOI: 10.1371/journal.pgen.1003242
- 16 Dyson NJ: Rb1: A prototype tumor suppressor and an enigma. *Genes Dev* 30(13): 1492-1502, 2016. PMID: 27401552. DOI: 10.1101/gad.282145.116
- 17 Cartwright P, Muller H, Wagener C, Holm K and Helin K: E2f-6: A novel member of the e2f family is an inhibitor of e2f-dependent transcription. *Oncogene* 17(5): 611-623, 1998. PMID: 9704927. DOI: 10.1038/sj.onc.1201975
- 18 Kong Y, Zhang L, Huang Y, He T, Zhang L, Zhao X, Zhou X, Zhou D, Yan Y, Zhou J, Xie H, Zhou L, Zheng S and Wang W: Pseudogene pdia3p1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway. *Cancer Lett* 407: 76-83, 2017. PMID: 28823960. DOI: 10.1016/j.canlet.2017.07.031
- 19 Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P and Miranda RN: Hematolymphoid neoplasms associated with rearrangements of pdgfra, pdgfrb, and fgfr1. *Am J Clin Pathol* 144(3): 377-392, 2015. PMID: 26276769. DOI: 10.1309/AJCPMORR5Z2IKCEM
- 20 David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z and Apperley JF: Durable responses to imatinib in patients with pdgfrb fusion gene-positive and bcr-abl-negative chronic myeloproliferative disorders. *Blood* 109(1): 61-64, 2007. PMID: 16960151. DOI: 10.1182/blood-2006-05-024828
- 21 Caunt CJ, Sale MJ, Smith PD and Cook SJ: Mek1 and mek2 inhibitors and cancer therapy: The long and winding road. *Nat Rev Cancer* 15(10): 577-592, 2015. PMID: 26399658. DOI: 10.1038/nrc4000
- 22 Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M and Ascierto PA: Mek inhibitors in the treatment of metastatic melanoma and solid tumors. *Am J Clin Dermatol* 18(6): 745-754, 2017. PMID: 28537004. DOI: 10.1007/s40257-017-0292-y
- 23 Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O and Hyman DM: Efficacy of mek inhibition in patients with histiocytic neoplasms. *Nature* 567(7749): 521-524, 2019. PMID: 30867592. DOI: 10.1038/s41586-019-1012-y
- 24 Zhao SJ, Jiang YQ, Xu NW, Li Q, Zhang Q, Wang SY, Li J, Wang YH, Zhang YL, Jiang SH, Wang YJ, Huang YJ, Zhang XX, Tian GA, Zhang CC, Lv YY, Dai M, Liu F, Zhang R, Zhou D and Zhang ZG: Sparc1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical wnt/beta-catenin signaling through stabilization of the wnt-receptor complex. *Oncogene* 37(8): 1049-1061, 2018. PMID: 29084211. DOI: 10.1038/nc.2017.403

- 25 Schmidt KM, Dietrich P, Hackl C, Guenzle J, Bronsert P, Wagner C, Fichtner-Feigl S, Schlitt HJ, Geissler EK, Hellerbrand C and Lang SA: Inhibition of mtorc2/riCTOR impairs melanoma hepatic metastasis. *Neoplasia* 20(12): 1198-1208, 2018. PMID: 30404068. DOI: 10.1016/j.neo.2018.10.001
- 26 Fan J, Lv Z, Yang G, Liao TT, Xu J, Wu F, Huang Q, Guo M, Hu G, Zhou M, Duan L, Liu S and Jin Y: Retinoic acid receptor-related orphan receptors: Critical roles in tumorigenesis. *Front Immunol* 9: 1187, 2018. PMID: 29904382. DOI: 10.3389/fimmu.2018.01187
- 27 Kannan K, Coarfa C, Chao PW, Luo L, Wang Y, Brinegar AE, Hawkins SM, Milosavljevic A, Matzuk MM and Yen L: Recurrent bcam-akt2 fusion gene leads to a constitutively activated akt2 fusion kinase in high-grade serous ovarian carcinoma. *Proc Natl Acad Sci USA* 112(11): E1272-1277, 2015. PMID: 25733895. DOI: 10.1073/pnas.1501735112
- 28 Shang J, Wang Z, Chen W, Yang Z, Zheng L, Wang S and Li S: Pseudogene chiap2 inhibits proliferation and invasion of lung adenocarcinoma cells by means of the wnt pathway. *J Cell Physiol* 234(8): 13735-13746, 2019. PMID: 30623445. DOI: 10.1002/jcp.28053
- 29 Wang Y, Ning Y, Alam GN, Jankowski BM, Dong Z, Nor JE and Polverini PJ: Amino acid deprivation promotes tumor angiogenesis through the gcn2/atf4 pathway. *Neoplasia* 15(8): 989-997, 2013. PMID: 23908598. DOI: 10.1593/neo.13262
- 30 Bunda S, Heir P, Metcalf J, Li ASC, Agnihotri S, Pusch S, Yasin M, Li M, Burrell K, Mansouri S, Singh O, Wilson M, Alamsahebpoor A, Nejad R, Choi B, Kim D, von Deimling A, Zadeh G and Aldape K: Cic protein instability contributes to tumorigenesis in glioblastoma. *Nat Commun* 10(1): 661, 2019. PMID: 30737375. DOI: 10.1038/s41467-018-08087-9
- 31 Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Hury JM, Kao YC, Huang SC, Singer S, Tap W, Schaefer IM and Fletcher CD: Sarcomas with cic-rearrangements are a distinct pathologic entity with aggressive outcome: A clinicopathologic and molecular study of 115 cases. *Am J Surg Pathol* 41(7): 941-949, 2017. PMID: 28346326. DOI: 10.1097/PAS.0000000000000846
- 32 Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K, Mayeur L, Italiano A, Michot A, Pierron G, Vasiljevic A, Ranchere-Vince D, Coindre JM and Tirode F: Clinicopathologic features of cic-nutml sarcomas, a new molecular variant of the family of cic-fused sarcomas. *Am J Surg Pathol* 43(2): 268-276, 2019. PMID: 30407212. DOI: 10.1097/PAS.0000000000001187
- 33 Zhou N, Schafer R, Li T, Fang M and Liu L: A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a lmna-ntrk1 gene fusion with durable clinical response to crizotinib: A case report. *BMC Cancer* 18(1): 842, 2018. PMID: 30134855. DOI: 10.1186/s12885-018-4749-z
- 34 Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balana C, Schoffski P, Grosso F, Lardelli P, Nieto A, Alfaro V and Demetri GD: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. *Eur J Cancer* 48(16): 3036-3044, 2012. PMID: 22749255. DOI: 10.1016/j.ejca.2012.05.012
- 35 De Sanctis R, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio P, Bastoni S, Bertuzzi AF, Quagliuolo V and Santoro A: Efficacy of trabectedin in advanced soft tissue sarcoma: Beyond lipo- and leiomyosarcoma. *Drug Des Devel Ther* 9: 5785-5791, 2015. PMID: 26604682. DOI: 10.2147/DDDT.S92395

Received June 30, 2019

Revised July 3, 2019

Accepted July 4, 2019